The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
PD-1 blockade in combination with epigenetic therapy to antagonize tumor mesenchymal program and drive therapeutic efficacy in an esophageal adenocarcinoma model.
 
Hyun Young Park
No Relationships to Disclose
 
Michael Topper
No Relationships to Disclose
 
Ashten Omstead
No Relationships to Disclose
 
Erin Grayhack
No Relationships to Disclose
 
Christopher Sherry
No Relationships to Disclose
 
Arul Goel
No Relationships to Disclose
 
Muhammad Anees
No Relationships to Disclose
 
Alisha Khan
No Relationships to Disclose
 
Ping Zheng
No Relationships to Disclose
 
Patrick Wagner
No Relationships to Disclose
 
Benny Weksler
No Relationships to Disclose
 
David Bartlett
No Relationships to Disclose
 
Ronan Kelly
Honoraria - Cardinal Health
Consulting or Advisory Role - Amgen; Aptitude Health; Astellas Pharma; AstraZeneca; BeiGene; Bristol-Myers Squibb; Clinical Education Alliance; Daiichi Sanyo; Eisai; Exact Sciences; Gilead Sciences; Jazz Pharmaceuticals; Medical Learning Group; Merck; MJH Life Sciences; Novocure; Onc Live; Oncohost; Peerview; Targeted Oncology; Toray Industries
Speakers' Bureau - Astellas Pharma; BeiGene; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Merck
Research Funding - Bristol-Myers Squibb (Inst); Lilly (Inst)
Expert Testimony - Bristol-Myers Squibb
Travel, Accommodations, Expenses - bristol-myers squibb
 
Vincent Lam
Consulting or Advisory Role - Anheart Therapeutics; AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Guardant Health; Iovance Biotherapeutics; Nuvectis Pharma; Pfizer; Takeda
Research Funding - AstraZeneca (Inst); BioNTech SE (Inst); BMS (Inst); Merck (Inst); Nuvalent, Inc. (Inst); Seagen (Inst)
 
Stephen Baylin
No Relationships to Disclose
 
Ali Zaidi
Stock and Other Ownership Interests - Previse; TG Therapeutics
Consulting or Advisory Role - BillionToOne; Delfi Diagnostics; Gilead Sciences; PrognomIQ
Research Funding - BillionToOne; Delfi Diagnostics; Exai Bio; Genece Health; Myriad Genetics; PrognomIQ; Roche/Genentech; Tempus